<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073811428007</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073811428007</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Communication</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Dehiscence of Corticosteroid-Induced Abdominal Striae in a 14-Year-Old Boy Treated With Bevacizumab for Recurrent Glioblastoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wheeler</surname>
<given-names>Helen</given-names>
</name>
<degrees>MBBS, FRACP</degrees>
<xref ref-type="aff" rid="aff1-0883073811428007">1</xref>
<xref ref-type="corresp" rid="corresp1-0883073811428007"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Black</surname>
<given-names>Jason</given-names>
</name>
<degrees>DipClinPharm</degrees>
<xref ref-type="aff" rid="aff2-0883073811428007">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Webb</surname>
<given-names>Suzanne</given-names>
</name>
<degrees>MBBS Hons, FRACP</degrees>
<xref ref-type="aff" rid="aff2-0883073811428007">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shen</surname>
<given-names>Han</given-names>
</name>
<degrees>BMed, MMSc</degrees>
<xref ref-type="aff" rid="aff3-0883073811428007">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0883073811428007">
<label>1</label>Royal North Shore Hospital, New South Wales, Australia</aff>
<aff id="aff2-0883073811428007">
<label>2</label>Cancer Care Centre Cairns Base Hospital, Queensland, Australia</aff>
<aff id="aff3-0883073811428007">
<label>3</label>Cure for Life Foundation Neuro-Oncology Laboratory, Prince of Wales Clinical School, University of New South Wales, New South Wales, Australia</aff>
<author-notes>
<corresp id="corresp1-0883073811428007">Helen Wheeler, MBBS, FRACP, Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia Email: <email>hrwheeler@optusnet.com.au</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>7</issue>
<fpage>927</fpage>
<lpage>929</lpage>
<history>
<date date-type="received">
<day>9</day>
<month>8</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>2</day>
<month>10</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>10</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Corticosteroids have been the mainstay for management of cerebral edema caused by leaky angiogenic vessels associated with high-grade brain tumors since the early 1960s. Chronic corticosteroid use can cause iatrogenic Cushing syndrome, which is associated with weight gain and abdominal striae (striae distensae). The anti–vascular endothelial growth factor therapy, bevacizumab, has recently been introduced for the management of recurrent glioblastoma. Vascular endothelial growth factor plays multiple roles in wound healing, including promoting angiogenesis, acting as a chemo-attractant for inflammatory cells, and stimulating collagen production. We report the first pediatric case of a 14-year-old boy with corticosteroid-induced abdominal striae who developed ulceration and dehiscence of the striae following the introduction of bevacizumab therapy. The combination of high-dose corticosteroids and anti–vascular endothelial growth factor therapy may cause significant complications, especially in children who are susceptible to abdominal striae and therefore should be avoided.</p>
</abstract>
<kwd-group>
<kwd>striae</kwd>
<kwd>bevacizumab</kwd>
<kwd>anti–vascular endothelial growth factor</kwd>
<kwd>corticosteroids</kwd>
<kwd>glioblastoma</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Elevated intracranial pressure caused by tumor cell proliferation and leaky tumor vasculature is the hallmark of glioblastoma<sup>
<xref ref-type="bibr" rid="bibr1-0883073811428007">1</xref>
</sup>; it can lead to deterioration in neurologic function along with severe headaches, nausea and vomiting, drowsiness, and eventually coma. Since the early 1960s, high-dose corticosteroids have played an important role in the management of cerebral edema.<sup>
<xref ref-type="bibr" rid="bibr2-0883073811428007">2</xref>
<xref ref-type="bibr" rid="bibr3-0883073811428007"/>–<xref ref-type="bibr" rid="bibr4-0883073811428007">4</xref>
</sup> Unfortunately, prolonged high-dose steroid use can lead to iatrogenic Cushing syndrome and significant decrease in quality of life for patients with recurrent brain tumors.<sup>
<xref ref-type="bibr" rid="bibr4-0883073811428007">4</xref>
</sup> In addition to weight gain, elevated blood glucose, myopathy, hypertension, and personality change, high-dose corticosteroids can cause significant skin atrophy and abdominal striae (striae distensae).<sup>
<xref ref-type="bibr" rid="bibr5-0883073811428007">5</xref>
</sup>  Idiopathic cutaneous striae occur in adolescents between the ages of 10 and 20 years,<sup>
<xref ref-type="bibr" rid="bibr6-0883073811428007">6</xref>
</sup> and this condition is common in adolescents receiving high-dose corticosteroids for organ transplantation.<sup>
<xref ref-type="bibr" rid="bibr5-0883073811428007">5</xref>
<xref ref-type="bibr" rid="bibr6-0883073811428007"/>–<xref ref-type="bibr" rid="bibr7-0883073811428007">7</xref>
</sup> A recent report describes striae ulceration in adult patients receiving combination corticosteroids and bevacizumab for primary glioma.<sup>
<xref ref-type="bibr" rid="bibr8-0883073811428007">8</xref>
</sup>
</p>
<p>Bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor A, was recently approved in Australia for the treatment of recurrent glioblastoma in adult patients.  Vascular endothelial growth factor is a proangiogenic factor that is expressed at high levels in brain tumors.<sup>
<xref ref-type="bibr" rid="bibr9-0883073811428007">9</xref>
</sup> The expression of vascular endothelial growth factor was shown to be associated with tortuous, disorganized, and highly permeable microvasculature, causing accumulation of fluid and plasma proteins peritumorally and in the surrounding brain and resulting in cerebral edema.<sup>
<xref ref-type="bibr" rid="bibr9-0883073811428007">9</xref>
</sup> Antiangiogenic inhibitors in solid tumors were shown to normalize vasculature and decrease tumor edema.<sup>
<xref ref-type="bibr" rid="bibr10-0883073811428007">10</xref>
</sup> Recent phase II clinical trials showed that in recurrent glioblastoma, bevacizumab demonstrated reduced symptoms of raised intracranial pressure and reduced corticosteroid usage; radiological improvements within 1 month of commencing bevacizumab therapy were also reported.<sup>
<xref ref-type="bibr" rid="bibr11-0883073811428007">11</xref>
<xref ref-type="bibr" rid="bibr12-0883073811428007"/>–<xref ref-type="bibr" rid="bibr13-0883073811428007">13</xref>
</sup>
</p>
<p>The use of bevacizumab in the pediatric setting is not well documented. It has been assessed in early phase trials for the treatment of pediatric patients with refractory or recurrent solid tumors, with demonstrated safety and tolerability,<sup>
<xref ref-type="bibr" rid="bibr14-0883073811428007">14</xref>,<xref ref-type="bibr" rid="bibr15-0883073811428007">15</xref>
</sup> and more recently it was used for the treatment of 4 patients with pontine gliomas and 12 patients with recurrent high-grade gliomas.<sup>
<xref ref-type="bibr" rid="bibr16-0883073811428007">16</xref>,<xref ref-type="bibr" rid="bibr17-0883073811428007">17</xref>
</sup>
</p>
<p>Here we present a 14-year-old boy who was treated with a combination of bevacizumab and high-dose corticosteroids for progressive glioblastoma. Preexisting corticosteroid-induced abdominal striae dehisced while on bevacizumab, causing significant morbidity and pain. Potentially this complication can arise when bevacizumab is administered to patients with steroid-induced striae.</p>
<sec id="section1-0883073811428007">
<title>Clinical Case</title>
<p>A 12-year-old boy was diagnosed with supratentorial glioblastoma in May 2008. Following debulking surgery, he received concurrent temozolomide and radiotherapy followed by 5 months of temozolomide. The patient progressed and was given 1 cycle of lomustine at which stage he developed severe neutropenia and all therapy was suspended. He remained stable for 7 months. In October 2009 he developed further symptoms and dexamethasone treatment was recommenced. In late December 2009, further debulking surgery was undertaken; by this stage, significant striae had developed (<xref ref-type="fig" rid="fig1-0883073811428007">Figure 1</xref>). Surgery was followed by 3 months of temozolomide and procarbazine. Corticosteroid doses fluctuated from December to April, but he was never steroid free. He progressed further in April 2010 and despite increasing the dose of dexamethasone to 12 mg his neurologic symptoms deteriorated. Bevacizumab 5 mg/kg in combination with irinotecan 125 mg/m<sup>2</sup> every 2 weeks was commenced in late April 2010. The patient initially responded to treatment with bevacizumab and irinotecan, allowing for the steroids to be slowly weaned. However, at steroid doses of less than 4 mg daily, he was experiencing worsening neurologic deficits with increased weakness in his right arm.</p>
<fig id="fig1-0883073811428007" position="float">
<label>Figure 1.</label>
<caption>
<p>Nondehisced striae seen on posterior axilla.</p>
</caption>
<graphic xlink:href="10.1177_0883073811428007-fig1.tif"/>
</fig>
<p>At the time of commencing bevacizumab, the large steroid-induced striae, which had been increasing in number since December 2009 on the abdomen, back, and thighs, started to ulcerate. The patient’s main symptom for these was pain, which was managed with opiate analgesia and regular dressing of the wounds to avoid infection. After 6 doses of bevacizumab plus irinotecan, the abdominal striae dehisced (<xref ref-type="fig" rid="fig2-0883073811428007">Figure 2</xref>), causing severe discomfort and pain. Bevacizumab and irinotecan were withdrawn in July 2010 without any improvements in the dehisced striae after discontinuation. The dose of dexamethasone was increased; however, his neurologic symptoms continued to deteriorate. The patient died in August 2010.</p>
<fig id="fig2-0883073811428007" position="float">
<label>Figure 2.</label>
<caption>
<p>Dehisced abdominal striae following 6 doses of bevacizumab plus irinotecan.</p>
</caption>
<graphic xlink:href="10.1177_0883073811428007-fig2.tif"/>
</fig>
</sec>
<sec id="section2-0883073811428007">
<title>Discussion</title>
<p>Prolonged corticosteroid use can cause both weight gain and redistribution resulting in increased abdominal fat. Corticosteroid can also reduce dermal collagen production<sup>
<xref ref-type="bibr" rid="bibr18-0883073811428007">18</xref>
</sup> and result in striae distensae, which can ulcerate if enough pressure is exerted.<sup>
<xref ref-type="bibr" rid="bibr4-0883073811428007">4</xref>,<xref ref-type="bibr" rid="bibr5-0883073811428007">5</xref>,<xref ref-type="bibr" rid="bibr19-0883073811428007">19</xref>
</sup> Bevacizumab is an anti–vascular endothelial growth factor therapy and has been shown to improve progression-free and overall survival in patients with recurrent glioblastoma.<sup>
<xref ref-type="bibr" rid="bibr11-0883073811428007">11</xref>
</sup>  Vascular endothelial growth factor inhibitors can cause rapid vessel normalization, resulting in improvement of symptoms and reduction in intracranial pressure in patients with recurrent glioblastoma.<sup>
<xref ref-type="bibr" rid="bibr11-0883073811428007">11</xref>
<xref ref-type="bibr" rid="bibr12-0883073811428007"/>–<xref ref-type="bibr" rid="bibr13-0883073811428007">13</xref>
</sup> In responding adult patients, this usually allows rapid reduction in the doses of corticosteroids. In the pediatric setting, however, care should be taken in using bevacizumab in the setting of corticosteroid-induced striae, and adolescents appear particularly susceptible to this problem.<sup>
<xref ref-type="bibr" rid="bibr7-0883073811428007">7</xref>
</sup>
</p>
<p>Vascular endothelial growth factor plays an essential role in the wound healing process as well as in establishing new vessels; it acts as a chemoattractant for other cells and is postulated to stimulate collagen deposition and epithelialization.<sup>
<xref ref-type="bibr" rid="bibr20-0883073811428007">20</xref>
</sup> It appears that the combination of corticosteroids and bevacizumab may synergize to reduce tensile strength in abdominal striae, resulting in ulceration and dehiscence in the striae, as was seen in the case presented here. Recently, Peters et al reported 4 adult cases (ranging in age from 38 to 47 years) with high-grade glioma who developed this complication while on concurrent corticosteroids and bevacizumab.<sup>
<xref ref-type="bibr" rid="bibr8-0883073811428007">8</xref>
</sup> Considering that the incidence of striae is more common in children,<sup>
<xref ref-type="bibr" rid="bibr6-0883073811428007">6</xref>
</sup> careful assessment is required while on anti–vascular endothelial growth factor therapy. In patients with preexisting striae care must be taken to avoid trauma to the area.</p>
<p> In patients responsive to anti–vascular endothelial growth factor therapy, corticosteroid doses can usually be rapidly reduced. If the corticosteroid dose cannot be reduced once bevacizumab is commenced, one must contemplate whether vascular endothelial growth factor is contributing to the cerebral edema and consider the involvement of other proangiogenic factors. In the presence of striae, continuing the combination of high-dose corticosteroids and anti–vascular endothelial growth factor therapy, particularly in the pediatric population, could lead to significant dehiscence problems. Attempts to taper corticosteroids as rapidly as possible should be made.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>The authors thank Joseline Ojaimi, PhD (Roche Products, Australia), for editorial support during the preparation of this report.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1-0883073811428007">
<label>Author Contributions</label>
<p>HW was involved in treating the patient, collecting patient data, analyzing data, and contributing to the first draft of the manuscript. JB was involved in clinical data collection and manuscript preparation. SW was involved in managing the patient database, case study, and manuscript preparation. HS was involved in manuscript preparation. All the authors were involved in the intellectual input of this case study.</p>
</fn>
<fn fn-type="conflict" id="fn2-0883073811428007">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0883073811428007">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="other" id="fn4-0883073811428007">
<label>Ethical Approval</label>
<p>No ethical approval was necessary.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073811428007">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plate</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Mennel</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Vascular morphology and angiogenesis in glial tumors</article-title>. <source>Exp Toxicol Pathol</source>. <year>1995</year>;<volume>47</volume>(<issue>2-3</issue>):<fpage>89</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr2-0883073811428007">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galicich</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>French</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery</article-title>. <source>Am Pract Dig Treat</source>. <year>1961</year>;<volume>12</volume>:<fpage>169</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr3-0883073811428007">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruderman</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Use of glucocorticoids in the palliative treatment of metastatic brain tumors</article-title>. <source>Cancer</source>. <year>1965</year>;<volume>18</volume>:<fpage>298</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr4-0883073811428007">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaal</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Vecht</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>The management of brain edema in brain tumors</article-title>. <source>Curr Opin Oncol</source>. <year>2004</year>;<volume>16</volume>(<issue>6</issue>):<fpage>593</fpage>–<lpage>600</lpage>.</citation>
</ref>
<ref id="bibr5-0883073811428007">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeo</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Sawyers</surname>
<given-names>ES</given-names>
</name>
</person-group>. <article-title>Steroid-induced striae in severe nephrotic syndrome</article-title>. <source>Kidney Int</source>. <year>2007</year>;<volume>72</volume>(<issue>8</issue>):<fpage>1038</fpage>.</citation>
</ref>
<ref id="bibr6-0883073811428007">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nigam</surname>
<given-names>PK</given-names>
</name>
</person-group>. <article-title>Striae cutis distensae</article-title>. <source>Int J Dermatol</source>. <year>1989</year>;<volume>28</volume>(<issue>7</issue>):<fpage>426</fpage>–<lpage>428</lpage>.</citation>
</ref>
<ref id="bibr7-0883073811428007">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Euvrard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kanitakis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cochat</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cambazard</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Claudy</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Skin diseases in children with organ transplants</article-title>. <source>J Am Acad Dermatol</source>. <year>2001</year>;<volume>44</volume>(<issue>6</issue>):<fpage>932</fpage>–<lpage>939</lpage>.</citation>
</ref>
<ref id="bibr8-0883073811428007">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peters</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Vredenburgh</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Desjardins</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Reardon</surname>
<given-names>DA</given-names>
</name>
</person-group>. <article-title>Ulceration of striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy</article-title>. <source>J Neurooncol</source>. <year>2011</year>;<volume>101</volume>(<issue>1</issue>):<fpage>155</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr9-0883073811428007">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>di Tomaso</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Duda</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Loeffler</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Sorensen</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Batchelor</surname>
<given-names>TT</given-names>
</name>
</person-group>. <article-title>Angiogenesis in brain tumours</article-title>. <source>Nat Rev Neurosci</source>. <year>2007</year>;<volume>8</volume>(<issue>8</issue>):<fpage>610</fpage>–<lpage>622</lpage>.</citation>
</ref>
<ref id="bibr10-0883073811428007">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Munn</surname>
<given-names>LL</given-names>
</name>
</person-group>. <article-title>Effect of vascular normalization by anti-angiogenic therapy on interstitial hypertension, peri-tumor edema and lymphatic metastasis: insights from a mathematical model</article-title>. <source>Cancer Res</source>. <year>2007</year>;<volume>67</volume>:<fpage>2729</fpage>–<lpage>2735</lpage>.</citation>
</ref>
<ref id="bibr11-0883073811428007">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Prados</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>PY</given-names>
</name>
<etal/>
</person-group>. <article-title>Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma</article-title>. <source>J Clin Oncol</source>. <year>2009</year>;<volume>27</volume>(<issue>28</issue>):<fpage>4733</fpage>–<lpage>4740</lpage>.</citation>
</ref>
<ref id="bibr12-0883073811428007">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kreisl</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma</article-title>. <source>J Clin Oncol</source>. <year>2009</year>;<volume>27</volume>(<issue>5</issue>):<fpage>740</fpage>–<lpage>745</lpage>.</citation>
</ref>
<ref id="bibr13-0883073811428007">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vredenburgh</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Desjardins</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reardon</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>HS</given-names>
</name>
</person-group>. <article-title>Experience with irinotecan for the treatment of malignant glioma</article-title>. <source>Neuro Oncol</source>. <year>2009</year>;<volume>11</volume>(<issue>1</issue>):<fpage>80</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr14-0883073811428007">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benesch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Windelberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sauseng</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors</article-title>. <source>Ann Oncol</source>. <year>2008</year>;<volume>19</volume>(<issue>4</issue>):<fpage>807</fpage>–<lpage>813</lpage>.</citation>
</ref>
<ref id="bibr15-0883073811428007">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glade Bender</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Adamson</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>Children's Oncology Group Study. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>(<issue>3</issue>):<fpage>399</fpage>–<lpage>405</lpage>.</citation>
</ref>
<ref id="bibr16-0883073811428007">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Macy</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Foreman</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2009</year>;<volume>75</volume>(<issue>4</issue>):<fpage>1148</fpage>–<lpage>1154</lpage>.</citation>
</ref>
<ref id="bibr17-0883073811428007">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narayana</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kunnakkat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chacko-Mathew</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Bevacizumab in recurrent high-grade pediatric gliomas</article-title>. <source>Neuro Oncol</source>. <year>2010</year>;<volume>12</volume>(<issue>9</issue>):<fpage>985</fpage>–<lpage>990</lpage>.</citation>
</ref>
<ref id="bibr18-0883073811428007">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oishi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>ZW</given-names>
</name>
<name>
<surname>Ohnuki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases</article-title>. <source>Br J Dermatol</source>. <year>2002</year>;<volume>147</volume>(<issue>5</issue>):<fpage>859</fpage>–<lpage>868</lpage>.</citation>
</ref>
<ref id="bibr19-0883073811428007">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vecht</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Hovestadt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Verbiest</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>van Vliet</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>van Putten</surname>
<given-names>WL</given-names>
</name>
</person-group>. <article-title>Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day</article-title>. <source>Neurology</source>. <year>1994</year>;<volume>44</volume>:<fpage>675</fpage>–<lpage>680</lpage>.</citation>
</ref>
<ref id="bibr20-0883073811428007">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folkman</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Angiogenesis: an organizing principle for drug discovery?</article-title> <source>Nat Rev Drug Discov</source>. <year>2007</year>;<volume>6</volume>(<issue>4</issue>):<fpage>273</fpage>–<lpage>286</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>